3,466 Shares in Enovis Co. (NYSE:ENOV) Acquired by McIlrath & Eck LLC

McIlrath & Eck LLC purchased a new stake in Enovis Co. (NYSE:ENOV) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,466 shares of the company’s stock, valued at approximately $152,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Quadrant Capital Group LLC raised its stake in Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock valued at $30,000 after purchasing an additional 239 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Enovis by 1.0% during the fourth quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock worth $1,136,000 after buying an additional 264 shares in the last quarter. Arizona State Retirement System raised its position in shares of Enovis by 2.6% in the fourth quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock valued at $711,000 after buying an additional 414 shares during the last quarter. UMB Bank n.a. raised its position in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after buying an additional 437 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its stake in shares of Enovis by 3.5% during the fourth quarter. New York State Teachers Retirement System now owns 13,538 shares of the company’s stock valued at $594,000 after buying an additional 457 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on ENOV. Needham & Company LLC lowered their target price on shares of Enovis from $64.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group reduced their target price on Enovis from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Finally, JMP Securities dropped their price objective on shares of Enovis from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

Enovis Trading Down 2.9%

Shares of ENOV opened at $34.45 on Wednesday. The stock’s fifty day simple moving average is $35.10 and its 200 day simple moving average is $41.32. Enovis Co. has a twelve month low of $29.32 and a twelve month high of $51.31. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $1.97 billion, a P/E ratio of -15.73 and a beta of 1.79.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.07. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. During the same period in the previous year, the company posted $0.50 EPS. The company’s revenue was up 8.2% compared to the same quarter last year. On average, equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.